Aflatoxin B 1 (AFB 1 ) is a risk factor for hepatocellular carcinoma in humans. Infant, but not adult, mice are sensitive to AFB 1 -induced liver carcinogenesis; a single dose during the neonatal period leads to hepatocellular carcinoma in adulthood. Earlier work defined the mutational spectrum in the gpt gene of gpt delta B6C3F1 mice 3 weeks after exposure to aflatoxin. In the present study, we examined the gpt spectrum 10 weeks postdosing and expanded the study to examine, at 3 and 10 weeks, the spectrum at a second locus, the red/gam genes of the mouse λEG10 transgene. Whereas the gpt locus is typically used to define local base changes, the red/gam genes, via the Spi -assay, often are used to detect more global mutations such as large deletions and rearrangements. Three weeks after dosing with AFB 1 , there was a 10-fold increase over the control in the Spi -mutant fraction (MF) in liver DNA; after 10 weeks, a further increase was observed. The MF in the gpt gene was also increased at 10 weeks compared with the MF at 3 weeks. No gender-specific differences were found in the Spi -or gpt MFs. Whereas Spi -mutations often signal large genetic changes, they did not in this specific case. The Spi -spectrum was dominated by GC to TA transversions, with one exceptionally strong hotspot at position 314. Using two genetic loci, the data show a strong preference for the induction of GC to TA mutations in mice, which is the dominant mutation seen in people exposed to aflatoxin.
In mice, the ability of aflatoxin B 1 (AFB 1 ) to produce covalent adducts in liver DNA of infant and adult animals differs, respectively, by 20-fold (Shupe and Sell, 2004) with correspondingly different incidences of hepatocellular carcinoma (HCC) (Busby and Wogan, 1984) . AFB 1 is a potent hepatocarcinogen in infant mice, but older mice are refractory to its carcinogenic effects because of changes in AFB 1 metabolism that reduce its ability to cause genotoxic damage (Dycaico et al., 1996; Hayes et al., 1991) . In infant B6C3F1 mice, a single dose of AFB 1 produces a high incidence of HCC in adult male mice but not in female mice (Vesselinovitch et al., 1972) . This gender disparity in HCC is seen in other rodent models and also parallels human epidemiological data. In humans, there is an established relationship between exposure to AFB 1 , levels of AFB 1 -DNA adducts in urine, and the incidence of HCC (Groopman et al., 2008) . Furthermore, the incidence of HCC in men is about two to four times higher than in women (El-Serag and Rudolph, 2007) . Elucidating the molecular details underlying age, species, and gender differences in carcinogenesis is central to the development of effective preventive strategies.
Carcinogenesis is characterized by sequential alterations in gene expression involving genetic and epigenetic mechanisms that can be induced by endogenous and/or environmental factors. Mutations produced by genotoxicants are essential for initiation of the carcinogenic process by most chemical carcinogens. Several studies have characterized the number and types of mutations produced in animal models shortly after treatment with AFB 1 and other genotoxic carcinogens (Chen et al., 2010; Woo et al., 2011) . However, little is known about the numbers and types of mutations that are present in the liver over the extended period required for the development of HCC.
Integrated bacterial reporter genes in transgenic mice have enabled characterization of somatic mutations that occur spontaneously or are produced by genotoxins that can cause cancer. Using transgenic gpt delta B6C3F1 mice, we recently examined the number and types of mutations produced in the liver after treatment of newborn animals with AFB 1 (Woo et al., 2011) . The gpt assay detected base pair substitutions, single base insertions, and small deletions, all of which have been associated with tumor development. Three weeks after AFB 1 administration, the gpt mutant fraction (MF) in the liver was increased approximately 20-fold in both males and females, indicating that shortly after exposure both sexes were at comparable risk of tumor-initiating mutations from AFB 1 -induced DNA damage.
The purpose of the present study was to assess the capability of AFB 1 to generate other types of DNA sequence changes including those driven by nonhomologous recombination Mutation assays. The gpt and Spi -assays were performed using genomic DNA isolated from mice injected with AFB 1 or vehicle (DMSO). Genomic DNA was extracted from 25 mg liver tissue using a RecoverEase DNA Isolation Kit (Agilent Technologies, Santa Clara, CA); subsequently, λEG10 phages were packaged in vitro from the genomic DNA using Transpack Packaging Extract (Agilent Technologies) following the manufacturer's instructions. The selection of 6-TG-resistant mutants and sequencing of the gpt gene were performed as described previously (Woo et al., 2011) .
The Spi -assay was performed by infecting XL1 Blue MRA Escherichia coli with rescued phage to estimate the total number of phage and XL1 Blue MRA (P2) E. coli to enumerate phage with the Spi -phenotype. Mutants were confirmed by growth on WL95 (P2) and XL1 Blue MRA E. coli strains. The Spi -mutant fraction was calculated as the number of confirmed mutants divided by the total number of packaged phage (Nohmi et al., 1996) .
Analysis of Spi
-mutants. Spi -phage were used to infect E. coli LE392 and incubated until lysis. Phage DNA was isolated from the Spi -lysate and a 5 kb segment containing the red and gam genes was amplified by PCR using primers: (5′-CTCTCCTTTGATGCGAATGCCAGA-3′) and (5′-GGAGTAATTATGCGGAACAGAATCATGC-3′). The PCR products were analyzed by agarose gel electrophoresis and purified for sequencing (QIAquick PCR Purification Kit, Qiagen). Sequencing of the gam gene was performed at the Biopolymers Facility at Harvard Medical School (Boston, MA) using the primer (5′-CCACTTTTATTGGCGATGAAAAGATGTTC-3′). Sequences were aligned with the λ gam gene (NC_001416) using NCBI Nucleotide Blast.
Statistical analyses.
Mutational spectra were compared using the AdamsSkopek test (Adams and Skopek, 1987; Cariello et al., 1994) . The MannWhitney nonparametric test was used to determine statistical significance of differences in MF.
RESULTS
AFB 1 adducts in liver DNA 3 weeks after treatment. The experimental protocol used in this investigation is shown in Figure 1 . Mice were injected ip with a single dose of 6 mg/kg AFB 1 on day 4 after birth. AFB 1 -DNA adduct levels in liver were analyzed 3 weeks later as described earlier. Our previous investigation quantified adduct levels up to 48 h after AFB 1 was administered (Woo et al., 2011) . Here we extended the period of observation to determine whether the persistent and more mutagenic AFB 1 -FAPY adduct had the potential to increase the mutation frequency in liver cells over an extended period. The previous analyses showed that both the AFB 1 -N 7 -guanine adduct and the imidazole ring-opened form (AFB 1 -FAPY) were present 48 h after dosing (Woo et al., 2011) . Three weeks after dosing, the AFB 1 -N 7 -guanine adduct was undetectable, whereas amounts of the highly mutagenic AFB 1 -FAPY persisted in liver DNA at a level of 1 adduct/10 7 nucleotides. This result suggested that additional mutations could be induced over the subsequent period of liver cell proliferation and prompted us to extend our original analyses of mutations in the gpt transgene.
The time point of 3 weeks in our previous study was chosen because by that age the liver had completed its initial phase of rapid growth during which mutations could be created through errors in repair or replication of DNA containing AFB 1 adducts. In the present study, the "fixation/expression" period was extended to determine how the mutant fraction in liver changed between 3 and 10 weeks after dosing. We recorded liver weight as a measure of age-related changes in cell proliferation and growth. At the time of AFB 1 administration on day 4 after birth, the liver in males and females weighed 54 ± 11 mg and 48 ± 13 mg, respectively; two days later (day 6), liver weights had increased significantly in both males (80 ± 23 mg) and females (74 ± 17 mg). At 25 days of age, which was 21 days after treatment, liver weights had increased by about 10-fold in both sexes (male 815 ± 73 mg; female 720 ± 50 mg). Thereafter, the rate of increase in liver weight slowed, nearly doubling during FIG. 1. Experimental scheme for treatment of 4-day old gpt delta B6C3F1 mice with 6 mg/kg AFB 1 , analysis of DNA adducts and gpt and Spi -mutation assays.
the subsequent 7 weeks and attaining an average weight of 1400 ± 374 mg in males and 970 ± 340 mg in females.
Mutation fraction in the gpt gene of AFB 1 -treated infant mice. Three and 10 weeks after treatment with a single dose of 6 mg/kg AFB 1 , λ transgenes were recovered from liver DNA by in vitro packaging. Growth of the λ phage on E. coli YG6020 expressing Cre recombinase produced chloramphenicol (CM)-resistant plasmids. Mutations in the gpt gene resulted in additional resistance to 6-TG. Tables 1 and 2 show the numbers of colonies resistant to CM and CM + 6-TG for each animal and the calculated gpt mutant fractions.
Tables 1 and 2 (also Fig. 2 ) depict that the average gpt MFs in the liver in AFB 1 -treated mice was greater at 10 weeks than at 3 weeks, with the increase in males (p = 0.02) during this 7-week period being greater than that found in females (p = 0.07). In DMSO-treated controls, the gpt MFs also increased, but the differences did not reach statistical significance (males p = 0.06; females p = 0.4); at 10 weeks, the gpt MF in the livers of males and females was the same (p = 0.55).
Sequencing of the 456 bp gpt gene in 157 6-TG-resistant colonies revealed similar types and positions of mutations at 3 weeks and 10 weeks. Table 3 summarizes the types of mutations found in the gpt gene in livers of 17 AFB 1 -treated mice (males and females) 10 weeks after treatment. As we previously observed, 3 weeks after AFB 1 treatment, the G:C to T:A transversion was the most frequent type of mutation present (55%) (Woo et al., 2011) . Figure 3 shows the distribution of base pair changes, insertions, and small deletions in the gpt Note. CM R = chloramphenicol resistant; 6-TGR = 6-thioguanine resistant. Note. CM R = chloramphenicol resistant; 6-TGR = 6-thioguanine resistant.
FIG. 2.
gpt MF in gpt delta B6C3F1 mouse liver 3 weeks or 10 weeks after treatment with 6 mg/kg AFB 1 or vehicle (DMSO) at day 4 after birth. gene at 10 weeks. Monte Carlo-based analysis revealed no differences between the gpt mutational spectra at 3 or 10 weeks after treatment (p > 0.05) (Adams and Skopek, 1987) .
TABLE 3 Summary of Mutation Types in the gpt
The Spi -assay is sensitive to mutations in the red and gam genes of the λEG10 transgene (Masumura et al., 2000) . Figure 4 , along with the data in Tables 4 and 5, illustrates that at 3 and 10 weeks after AFB 1 treatment there was a 10-to 20-fold increase in the Spi -MF in liver DNA compared with vehicle-treated control mice. Equal fractions of Spi -mutations were found in male and female mice at 3 weeks. At 10 weeks, the Spi -MF in AFB 1 -treated mice was increased significantly in both males (p = 0.004) and females (p = 0.02) compared with the 3-week MF.
Spi
-mutants from 10-week mice were first characterized by PCR amplification of a 5 kb segment of the λEG10 transgene containing both the gam and red genes. All of the mutants produced a full-length 5 kb PCR product indicating that there were no large deletions or other types of rearrangements in the gam and red gene coding sequences. Mutations in the gam gene alone can show the Spi -phenotype (Singer, 1971) . Therefore, we decided to perform sequence analysis of gam to identify any base substitutions or small insertions/deletions characteristic of those produced by AFB 1 . Figure 5 shows the sequence changes that were identified in the gam gene of Spi -phage isolated from AFB 1 -treated mice and DMSO-treated controls. Ninety-six Spi -λEG10 phage were sequenced from 10 AFB 1 -treated mice. Only 14 mutants were available for sequence analysis from the 6 control mice treated with DMSO. Base pair substitutions were once again the predominant type of mutation, representing 88% of total mutations in AFB 1 -treated mice. There were no significant gender differences either in the type of mutation in the gam gene (Table 6 ). The C:G to A:T transversion mutation at nucleotide 314 is a hot spot that was found in all 10 AFB 1 -treated mice analyzed at 10 weeks, representing approximately 50% of the sequenced mutants. The most plausible explanation for this mutation is the formation of an AFB 1 -Gua adduct on the G-containing strand. Frameshifts resulting from single base pair deletions or insertions represented the next most abundant class of mutations (22% of total). Single base pair deletions predominated in limited number of mutants available for analysis in the 10-week control group.
DISCUSSION
Cancer development involves the acquisition of proliferative and invasive phenotypes through the accumulation of genetic variation spontaneously or through exposures to environmental carcinogens. The multiple genetic changes associated with carcinogenesis include point mutations, chromosomal rearrangements, and changes in gene copy number (Futreal et al., 2004) . AFB 1 , one of the most potent known liver carcinogens in humans and animal models, has been shown to be a potent mutagen in bacterial and mammalian cells. Previous work using Note. The percentage of each type of mutation is shown in parentheses. a Because few mutants were available for analysis, data from male and female mice were combined. bacterial reporter genes in transgenic mice established that neonatal exposure to AFB 1 leads to a 20-fold increase in the frequency of point mutations in the gpt gene in the liver (Chen et al., 2010; Woo et al., 2011) . In the present investigation, we studied the ability of AFB 1 to induce mutations in the gam and red genes of a λEG10 reporter in mouse liver. Mutations in these genes produce the Spi -phenotype that can be identified by the ability to grow on P2 lysogenic E. coli strains. This assay is sensitive to large deletions and rearrangements in the gam and red genes as well as small deletions, insertions, and base pair substitutions that disrupt transcription and translation of these genes.
In conjunction with the results of our previous study, the findings in the present study establish the ability of AFB 1 to induce a broad range of mutation types in the liver DNA, including base pair substitutions and frameshifts resulting from small deletions and insertions. Earlier analyses showed a 13-to 15-fold increase in the MF of the gpt transgene at 3 weeks after treatment of 4-day-old mice (Woo et al., 2011) ; our present findings show that the MF continued to increase up to 20-fold over DMSO-treated controls at 10 weeks thereafter. These results are in agreement with another study that found a 22-fold increase in base substitution and frameshift mutations in the cII transgene of neonatal Big Blue B6C3F1 mice 6 weeks after treatment with AFB 1 (Chen et al., 2010) . The slower increase in MF in the liver from 3 to 10 weeks was very likely due to the decrease in growth rate of the liver after 3 weeks. Liver weight increased approximately 10-fold during the initial 3-week period, and subsequently doubled in size over the next 7 weeks. Cell proliferation provides opportunities for fixation of mutations at damaged sites in DNA through replication errors. Reynolds et al. (2004) reported a 27-fold difference in the proliferation index between 4-week and 12-week-old B6C3F1 mice. Thus, during the initial 3-week period, a greater number of AFB 1 -DNA adducts are present along with greater opportunity for them to cause mutations when cells are in S-phase during this period of rapid liver growth.
The strong mutagenic signal in the Spi -assay from the liver of AFB 1 -treated animals is particularly noteworthy. The sequence characteristics of deletions found in gpt delta mice after treatment with various agents include -1 bp frameshifts and larger deletions (> 10 kb) containing junction sequences of limited homology that could result from end joining of double strand breaks (Horiguchi et al., 2001; Masumura et al., 2000; Nohmi et al., 1999) . The molecular characteristics of the Spi -mutants from the liver of AFB 1 -treated mice differ from those found in the aforementioned studies. In the present work on aflatoxin, there were some small deletions and frameshifts observed, but point mutations were more common. A significant number of base substitutions resulted in the appearance of a stop codon in the gam gene, which presumably resulted in a halt in translation in both the gam and the contiguous redAB genes. Approximately 50% of all base substitution mutations (44 out of 98 sequenced mutations) were found at a single site: the C:G to A:T transversion that occurred at base pair 314. This mutation was not seen among the 15 Spi -mutants analyzed from DMSO-treated animals, which would indicate that it is a hot spot for AFB 1 -induced mutations. This transversion mutation in the gam gene results in the substitution of glutamate for an alanine residue that is located in one of the two small helices of the gam protein that functions to anchor larger helical regions for proper binding to the RecBCD complex (Court et al., 2007) . The charged glutamate residue may prevent this interaction. Inhibition of the RecBC complex by gam is required for initiation of the rolling circle mode of lambda replication that generates linear concatemers of DNA that can be packaged into infectious phage (Furth and Wickner, 1983) . Gam -phage are confined to the closed-circular form of replication, producing single circular genomes that are not substrates for packaging and consequently are unable to produce plaques. Recombination between circles, however, produces dimers that can be packaged to form infectious progeny. The λEG10 genome contains several Chi sequences that promote recombination by RecBC, facilitating the concatenation of circular genomes and formation of infections particles by gam -phage (Smith, 1983) . This could partly explain our observation of the Spi -phenotype resulting from the transversion at base pair 314. However, a full explanation will require a better understanding of the basis for Spi -selection on P2 lysogenic strains. The strong mutagenicity of AFB 1 at base pair 314 may result from its preferential reaction with AFB 1 -8,9-oxide, lack of repair, or susceptibility to replication errors. It is also possible, however, that unexpected variables in the conditions used for selection of the Spi -phenotype are responsible for the apparent prevalence of this mutant in AFB 1 -treated animals.
Aflatoxin DNA adducts that could be responsible for these mutations include AFB 1 -N 7 -Gua and the multiple AFB 1 -FAPY adducts. These adducts block replication in in vitro assays (Johnston and Stone, 2000; Levy et al., 1992; Refolo et al., 1985) . AFB 1 -FAPY exists in two rotameric forms (major and minor), which differ substantially with respect to lethal and mutagenic potencies in a bacterial reporter system. The major adduct is a particularly strong block for replication by both normal and bypass DNA polymerases, whereas the minor adduct is most potent at causing base substitutions (Smela et al., 2002) , specifically G to T transversions. The presence of AFB 1 -FAPY in liver DNA 3 weeks after dosing indicates that this highly persistent adduct has multiple opportunities to cause genetic alterations over an extended period of time during hepatocarcinogenesis.
The increase in the Spi -MF (10-fold) was a little less than half that of the gpt MF (20-fold) measured at 10 weeks of age (see Figs. 2 and 4) . It is difficult to compare mutational potencies in different loci, especially in loci that encode such disparate functions as those of the gpt and gam genes. Nevertheless, the data from these two loci support the view that aflatoxin is a good point mutagen. If it induced frequent more global genetic changes, we would have expected to have seen such mutagenic events among the sequenced Spi -mutants. In this respect, the types of Spi -mutants induced by AFB 1 were similar to those reported for 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP) and aminophenylnorharman, which were dominated by small deletions and single base substitutions (Masumura et al. , 2003 . The absence of large deletions and rearrangements in the gam and red genes of Spi -phage in our experiments is in contrast to the reported ability of AFB 1 to cause these types of recombinantdriven changes in yeast (Sengstag et al., 1996) and lymphoid cells in culture (Preisler et al., 2000; Stettler and Sengstag, 2001) as well as reports of its ability to cause micronuclei and sister chromatid exchanges (Busby and Wogan, 1984) . Further studies will be required to clarify these apparent discrepancies to understand the role of clastogenic activities of AFB 1 in HCC.
The infant mouse model provides a unique environment in which to investigate the extended process of carcinogenesis following a single exposure to a carcinogen such as AFB 1 . A significant finding in this study is the absence of gender differences in gpt or Spi -MFs in liver DNA up to 10 weeks after treatment. On this basis, it would appear that the potential for initiation of HCC development exists in animals of both sexes; eventually, however, female mice develop a much lower incidence of HCC than do males (Vesselinovitch et al., 1972) . If formation of mutations and adducts are central to carcinogenesis, this study helps to identify periods later than 10 weeks as the critical periods in defining the sex differences in carcinogenic outcome. In rodent models of HCC, development of premalignant lesions and their rate of progression to malignancy can be modulated by sex hormones and tumor-promoting cytokines (Maeda et al., 2005) . Cytokine expression by injured hepatocytes results in the recruitment of inflammatory cells that aid in the process of tumor development (He et al., 2010) . The discovery that cytokine expression can be suppressed by estrogenic hormones provides one possible mechanism responsible for the gender difference in incidence of chemically induced HCC in rodents (Naugler et al., 2007) . Despite a wealth of information, it is still unclear how the inflammatory process promotes the genetic and/ or epigenetic changes required to complete the carcinogenic process. One possibility is that chronic exposure to reactive oxygen species (ROS) or other reactive products of inflammatory cells promotes further mutagenesis and genomic instability in initiated hepatocytes. Further evaluation of the genetic changes that occur in cells as they progress to malignancy will help to clarify the biochemical mechanisms responsible for tumor progression and identify targets for preventive strategies. 
